Related Experiment Video

Updated: Oct 11, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Oral insulin and the induction of tolerance in man: reality or fantasy?

P Pozzilli, M Gisella Cavallo

    Diabetes/Metabolism Research and Reviews
    |October 12, 2000
    PubMed

    Insights

    Oral insulin therapy did not preserve beta-cell function in recent-onset Type 1 diabetes patients. These findings question the effectiveness of oral tolerance induction once the autoimmune process is active.

    Area of Science:

    • Immunology
    • Endocrinology
    • Diabetes Research

    Background:

    • Type 1 diabetes involves an autoimmune attack on insulin-producing beta cells.
    • Oral insulin is being investigated for its potential to induce immune tolerance and prevent Type 1 diabetes.
    • Previous trials, including the DPT1 study, explored oral insulin for Type 1 diabetes prevention.

    Discussion:

    • This study evaluated oral insulin (2.5 mg and 7.5 mg daily) in recent-onset Type 1 diabetes patients over one year.
    • No significant effect on residual beta-cell function, measured by C-peptide secretion, was observed.
    • The results challenge the established understanding of oral tolerance induction in active autoimmune diseases.

    Key Insights:

    • Oral insulin administration did not preserve beta-cell function in individuals newly diagnosed with Type 1 diabetes.
    • The timing of intervention appears critical, as tolerance induction may be ineffective once the immune process is underway.
    • Current therapeutic strategies for Type 1 diabetes may need re-evaluation regarding oral tolerance induction.

    Outlook:

    • Further research is needed to understand the window for effective immune tolerance induction in Type 1 diabetes.
    • Investigating alternative strategies or earlier intervention points for preventing Type 1 diabetes progression is crucial.
    • Exploring mechanisms beyond simple tolerance induction might be necessary for therapeutic success.

    More Related Videos

    An In Ovo Model for Testing Insulin-mimetic Compounds06:09

    An In Ovo Model for Testing Insulin-mimetic Compounds

    Published on: April 23, 2018

    Related Concept Videos

    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    Type I Diabetes II: Pathophysiology01:26

    Type I Diabetes II: Pathophysiology

    Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
    Insulin Formulations: Types and Delivery01:27

    Insulin Formulations: Types and Delivery

    Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
    Short-acting insulins are divided into rapid-acting...
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
    Insulin: Biosynthesis, Chemistry, and Preparation01:25

    Insulin: Biosynthesis, Chemistry, and Preparation

    The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
    Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
    Type I Diabetes I: Introduction01:12

    Type I Diabetes I: Introduction

    Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...